
    
      The trial is randomized (1:1 alirocumab to placebo), double-blinded, placebo-controlled with
      a cross-over design. The trial will last 10 months and includes a 10 week washout period
      between study phases.Twenty adult subjects with dyslipidemia secondary to nephrotic syndrome
      and treated with atorvastatin will be recruited. Alirocumab or placebo will be
      co-administered biweekly. Safety, efficacy chemistries, vital signs, anthropometry and
      monitoring for adverse events also will done at each visit.
    
  